| Jul 18 |
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
|
| Jul 18 |
Alnylam Stock Is a Blockbuster Biopharma In the Making
|
| Jul 14 |
Alnylam Pharmaceuticals (NASDAQ:ALNY) rallies 3.8% this week, taking five-year gains to 246%
|
| Jul 11 |
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
|
| Jul 10 |
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
|
| Jul 9 |
7 Cheap Biotech Stocks With Major Upside Potential
|
| Jul 8 |
Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win
|
| Jul 7 |
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
|
| Jul 5 |
Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings
|
| Jul 4 |
An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued
|
